SKB BIO (06990.HK) -11.400 (-2.404%) Short selling $53.99M; Ratio 9.430% announced that it will present multiple company-led clinical research results at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 29 to June 2 in Chicago, Illinois, the US. Among them, two pivotal studies have been selected for oral presentations in the metastatic non-small cell lung cancer session, including the TROP2-targeting antibody-drug conjugate (ADC) sac-TMT (Jiatelai) and the next-generation selective RET inhibitor A400/EP0031 (Ningtelai).SKB BIO is currently quoted at HKD474.2, up 4.54%, with a turnover of 435,700 shares, involving HKD210 million. (jl/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-26 16:25.)Related NewsNomura Raises SKB BIO (06990.HK) TP to HKD544.42; Encouraging Lung Cancer Data
AASTOCKS Financial News